Barclays upgrades Croda on activist investor, cost cutting plans
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
BMO on Pfizer (PFE) and Trump Deal: 'Announcement serves as a positive to the BioPharma sector'
September 30, 2025 12:44 PM EDTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $30.00 price target on Pfizer (NYSE: PFE).
The analyst comments "Pfizer and Trump announcement looks to address push from Trump administration for MFN pricing in the US. President Trump's announcement with Pfizer appears to reduce the cost of products for Medicaid customers and form an agreement that new product launches will be listed at the MFN price. While commentary from the call suggests... More
